272 related articles for article (PubMed ID: 27612952)
1. Molecular mechanisms for vascular complications of targeted cancer therapies.
Gopal S; Miller KB; Jaffe IZ
Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis.
Seijkens TTP; Lutgens E
Curr Opin Lipidol; 2018 Oct; 29(5):381-388. PubMed ID: 30074493
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Herrmann J
Curr Oncol Rep; 2016 Jun; 18(6):33. PubMed ID: 27099141
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
7. Renal Toxicities of Targeted Therapies.
Abbas A; Mirza MM; Ganti AK; Tendulkar K
Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
9. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.
Herrmann J; Yang EH; Iliescu CA; Cilingiroglu M; Charitakis K; Hakeem A; Toutouzas K; Leesar MA; Grines CL; Marmagkiolis K
Circulation; 2016 Mar; 133(13):1272-89. PubMed ID: 27022039
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular toxicities of biological therapies.
Ryberg M
Semin Oncol; 2013 Apr; 40(2):168-77. PubMed ID: 23540742
[TBL] [Abstract][Full Text] [Related]
11. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
12. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ
Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908
[TBL] [Abstract][Full Text] [Related]
13. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
14. Management of pulmonary toxicity associated with targeted anticancer therapies.
Teuwen LA; Van den Mooter T; Dirix L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1695-707. PubMed ID: 26293379
[TBL] [Abstract][Full Text] [Related]
15. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
Mukai M
Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
[TBL] [Abstract][Full Text] [Related]
16. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
17. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Rea D
Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
[TBL] [Abstract][Full Text] [Related]
18. Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers.
Escalante CP; Lu M; Marten CA
Curr Hypertens Rev; 2016; 12(2):112-20. PubMed ID: 26931476
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicities from targeted therapies: a review.
Barber NA; Ganti AK
Target Oncol; 2011 Dec; 6(4):235-43. PubMed ID: 22076388
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of molecularly targeted agents.
Hedhli N; Russell KS
Curr Cardiol Rev; 2011 Nov; 7(4):221-33. PubMed ID: 22758623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
